Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000938
Chunk: 60

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 60
---
79                                     
 Attention: Depositary Receipts Group                         
 E-mail Address: DR_Global_CSM@jpmorgan.com                   |

| -33- |

or at such other address and/or email address
and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party three (3)
Business Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent
or other communication, (B) mechanically or electronically generated by the sender’s email account containing the time, date, and
recipient email address, as applicable or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence
of personal service, or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above,
respectively.

(g) . This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and permitted
assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor,
including by merger or consolidation. The Investor may not assign its rights or obligations under this Agreement.

(h) . This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns and, except as set forth in Section 9 with respect to those persons entitled to indemnity thereunder, is not for the benefit
of, nor may any provision hereof be enforced by, any other Person.

(i) .
The Company shall afford the Investor and its counsel with the opportunity to review and comment upon, shall consult with the Investor
and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its counsel on,
any press release, SEC filing or any other public disclosure by or on behalf of the Company relating to the Investor, its purchases hereunder
or any aspect of the Securities, the Transaction Documents or the transactions contemplated thereby (other than any press release, SEC
filing or other public disclosure that contains disclosures substantially similar to disclosures previously reviewed by the Investor or
its counsel), not less than 24 hours prior to the issuance, filing or public disclosure thereof. The Investor must be provided with a
final version of any portion of such press release, SEC filing or other public disclosure relating to the Investor, its purchases hereunder
or any aspect of the Securities, the Transaction Documents or the transactions contemplated thereby at least